Skip to content
Peptide research

Mod GRF 1-29

Also known as Modified GRF · CJC-1295 no DAC · CJC-1295 without DAC
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

A modified GHRH fragment that triggers pulsatile growth hormone release. The case is mostly mechanistic: preserved pulsatility and GHRP synergy have moderate support; claimed gains in body composition and sleep are low or speculative. Human safety data are minimal, and the resulting IGF-1 rise carries an unresolved, theoretical tumor concern. Not FDA-approved; most supply consists of unregulated products sold online.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Mod GRF 1-29, also known as CJC-1295 without DAC (Drug Affinity Complex), is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of GHRH with four key amino acid substitutions. The modifications occur at positions 2 (D-Ala to prevent DPP-IV cleavage), 8 (Gln to prevent asparagine rearrangement), 15 (Ala to enhance bioactivity), and 27 (Leu to prevent methionine oxidation). These tetrasubstitutions create a significantly more stable peptide than native GHRH or the earlier sermorelin (unmodified GRF 1-29), resulting in a half-life of approximately 30 minutes compared to sermorelin's ~10 minutes.

Mod GRF 1-29 works by binding to GHRH receptors on the anterior pituitary gland, stimulating the pulsatile release of growth hormone (GH). Unlike exogenous GH injection, which provides a flat, supraphysiological dose, Mod GRF 1-29 works with the body's natural feedback mechanisms to produce GH in physiological pulses. GHRH analogs and growth hormone-releasing peptides (GHRPs) such as Ipamorelin or GHRP-6 act synergistically through complementary pathways: GHRH analogs amplify the GH pulse while GHRPs initiate it.

Mod GRF 1-29 is one of the most widely used peptides in anti-aging and performance optimization protocols. Its clinical predecessor, CJC-1295 with DAC, was studied in randomized controlled trials that demonstrated sustained GH and IGF-1 elevation for days to weeks. The DAC form raises basal GH while preserving pulsatility. A comparative clinical advantage in pulsatility or safety for Mod GRF 1-29 has not been established.

How it works in the body

A tetra-substituted analog of GHRH (amino acids 1-29) with four amino acid changes that dramatically extend its half-life from ~7 minutes to ~30 minutes. It activates the same GHRH receptor as the native hormone, stimulating pulsatile GH release. Unlike CJC-1295 with DAC, it does not produce sustained GH elevation — it mimics natural pulses.

Research overview

The clinical evidence for Mod GRF 1-29 draws primarily from research on its parent compound CJC-1295 (with DAC) and the broader GHRH analog class including sermorelin. The pivotal study by Teichman et al. (JCEM 2006, PMID 16352683) was a randomized, placebo-controlled, double-blind trial in healthy adults that demonstrated CJC-1295 produced dose-dependent GH increases of 2-10 fold sustained for 6+ days and IGF-1 increases of 1.5-3 fold sustained for 9-11 days after a single injection. The estimated half-life was 5.8-8.1 days. After multiple doses, IGF-1 remained elevated for up to 28 days. Sermorelin (the unmodified GRF 1-29) has been more extensively studied in clinical trials and was previously FDA-approved (as Geref) for GH deficiency in children. The tetrasubstituted Mod GRF 1-29 specifically has limited published clinical trial data, but is widely used based on GHRH-class pharmacology and the CJC-1295 data.

Who researches Mod GRF 1-29?

Commonly researched by

  • People exploring muscle growth and performance

    Researched for potential effects on lean mass, strength, or athletic performance.

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People exploring sleep quality improvement

    Researched for effects on sleep architecture, circadian rhythm, or sleep quality.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(5)

Rated by level of concern

  • Injection site reactions (redness, swelling, pain)

    High

    PMID 20554713 (tesamorelin pooled phase 3 safety); PMID 20101189 (Falutz JAIDS 2010 RCT with safety extension)

  • Flushing and warmth

    Low

    Human GHRH/sermorelin administration experience (transient facial flushing is a documented class effect); no Mod GRF 1-29-specific primary trial

  • Water retention and joint stiffness

    Moderate

    PMID 20554713; PMID 20101189

  • Potential impact on blood glucose regulation

    Moderate

    PMID 20554713 (tesamorelin phase 3 glycemic safety). PMID 21124215 is a narrative review (Curr Opin Infect Dis 2011, HIV lipohypertrophy) - background only. PMID 22495074 removed: it reports IMPROVED metabolic profile with visceral fat loss and does not support a glycemic-harm claim.

  • Theoretical tumor growth promotion (via IGF-1 elevation)

    Theoretical

    Class labeling precaution for GHRH analogs (sermorelin, tesamorelin); no positive human trial evidence

Interaction summary(8)

Rated by direction with this peptide

  • GHRPs / ghrelin-receptor agonists (ipamorelin, GHRP-6, GHRP-2, hexarelin, MK-677)

    SynergisticModerate

    Co-administration produces supra-additive GH release in humans via complementary GHRH-receptor and GHS-R1a signaling with somatostatin withdrawal - amplifying both the intended effect and GH-related adverse effects such as fluid retention and insulin resistance. Human data are in patient populations and with native GHRH/GHRH(1-29), not Mod GRF 1-29.

    PMID 9509075; PMID 7883854; PMID 9186261 (review)

  • Exogenous growth hormone (somatropin)

    CautionModerate

    Additive GH/IGF-1 exposure with no added benefit rationale - exogenous GH also suppresses endogenous GHRH-driven secretion through IGF-1 feedback, so using both mainly increases arthralgia, edema and hyperglycemia risk. Mechanistic inference; no co-administration trial exists.

    Mechanistic; somatropin labeling and GH-axis feedback physiology (no human interaction study)

  • Somatostatin analogs (octreotide, lanreotide, pasireotide)

    CautionModerate

    Directly antagonistic - somatostatin-receptor agonists suppress pituitary GH secretion and will blunt or abolish the GH response to Mod GRF 1-29. The consequence is loss of effect plus counter-therapeutic interference in anyone treated for acromegaly, not direct toxicity.

    Mechanistic (SSTR-mediated GH suppression); GHRH-stimulation-test pharmacology

  • Glucocorticoids (prednisone, dexamethasone, chronic supraphysiologic steroids)

    CautionModerate

    Chronic glucocorticoid excess blunts GHRH-stimulated GH release and impairs IGF-1 action, reducing expected response while compounding hyperglycemia risk.

    Mechanistic; established blunting of the GH response to GHRH in glucocorticoid excess (class-level endocrine physiology, no Mod GRF 1-29 data)

  • Insulin and other antidiabetic agents (sulfonylureas, GLP-1 agonists, metformin)

    CautionModerate

    GH-induced insulin resistance may raise glucose and increase antidiabetic dose requirements; monitor glycemia and adjust rather than assume stability. Inferred from GH physiology and tesamorelin glycemic safety data - no direct interaction study.

    PMID 20554713 (tesamorelin glycemic safety). PMID 22495074 removed (reports improved metabolic profile, does not support this direction); PMID 21124215 is a review, background only.

  • Cholinergic agents / acetylcholinesterase inhibitors (pyridostigmine)

    SynergisticLow

    Cholinergic agonism lowers hypothalamic somatostatin tone and potentiates GHRH-stimulated GH release - a pharmacologic amplifier used in GH-stimulation testing, not a clinical benefit. Practical relevance at therapeutic pyridostigmine doses is unquantified.

    Human pyridostigmine/GHRH stimulation-test literature (Ghigo/Massara group); no specific PMID could be confirmed.

  • Thyroid hormone status / levothyroxine

    CautionLow

    Hypothyroidism alters the somatotroph response to GHRH, and increased GH activity can shift peripheral T4-to-T3 conversion - thyroid function is worth checking before and during use.

    PMID 8961133 (J Pediatr Endocrinol Metab 1996, a small pediatric study of pituitary enlargement in primary hypothyroidism; weak support); GH-thyroid axis physiology

  • GH stimulation testing / IGF-1 diagnostic workup

    CautionModerate

    Recent GHRH-analog dosing invalidates GH-stimulation and IGF-1-based diagnostic testing for acromegaly or GH deficiency; disclose use and allow washout before endocrine evaluation.

    Mechanistic; GHRH is itself a diagnostic stimulation agent. PMID 16352683 removed - that paper is a CJC-1295-with-DAC phase 1 pharmacology study and says nothing about diagnostic-test interference.

Known risks(5)

  • Injection site reactions (redness, swelling, pain)

    Mild

    Common with subcutaneous injection. Transient redness, itching, or pain at the injection site. Generally mild and self-resolving.

  • Flushing and warmth

    Mild

    GHRH analogs can cause transient facial flushing and a sensation of warmth shortly after injection, lasting minutes.

  • Water retention and joint stiffness

    Mild to Moderate

    Elevated GH/IGF-1 can cause fluid retention, leading to bloating, joint stiffness, and carpal tunnel-like symptoms. Typically dose-dependent and reversible.

  • Potential impact on blood glucose regulation

    Moderate

    GH elevation can reduce insulin sensitivity and increase fasting blood glucose. Patients with diabetes or insulin resistance should use with caution and monitor glucose levels.

  • Theoretical tumor growth promotion (via IGF-1 elevation)

    Theoretical

    Chronic IGF-1 elevation has been associated with increased risk of certain cancers in epidemiological studies. Patients with active malignancies should not use GH secretagogues. Long-term cancer risk data specific to Mod GRF 1-29 is not available.

Drug interactions(4)

  • Exogenous growth hormone (somatotropin)

    Using Mod GRF 1-29 with exogenous GH is generally not recommended, as it can lead to excessive GH levels and suppress natural GH pulsatility. The purpose of GHRH analogs is to stimulate endogenous GH production.

  • Insulin and oral diabetes medications

    GH elevation can increase insulin resistance and blood glucose. Patients on diabetes medications may need dose adjustments. Blood glucose monitoring recommended.

  • Glucocorticoids (prednisone, dexamethasone)

    Chronic glucocorticoid use suppresses the GH/IGF-1 axis and may blunt the response to GHRH analogs. Additionally, both GH elevation and glucocorticoids impair glucose tolerance.

  • Somatostatin analogs (octreotide, lanreotide)

    Somatostatin inhibits GH release and directly opposes GHRH signaling. Co-administration would counteract the effects of Mod GRF 1-29.

Research & benefits

Evidence base

Evidence Level
Limited Evidence
Total Studies
50
Human Studies
No compound-specific human participant count established; cited human studies used DAC-containing CJC-1295 or sermorelin.

Direct clinical trial data for tetrasubstituted Mod GRF 1-29 is limited. The strongest evidence comes from the CJC-1295 (with DAC) RCTs showing sustained GH/IGF-1 elevation in healthy adults. Sermorelin (unmodified GRF 1-29) had sufficient clinical data for prior FDA approval. The specific tetrasubstituted form is widely used based on GHRH-class pharmacology and mechanistic rationale, with substantial anecdotal and clinical practice evidence but limited published controlled trials of the exact compound.

Researched for(5)

Rated by confidence in the evidence

  • Dose-dependent increase in growth hormone levels

    Speculative

    Sustained multi-day GH rise is documented for CJC-1295 with DAC, not for Mod GRF 1-29.

    No primary source for Mod GRF 1-29 at this magnitude/duration. The 2-10 fold, multi-day profile belongs to CJC-1295 WITH DAC (Teichman et al., JCEM 2006, PMID 16352683), a distinct molecule with a 5.8-8.1 day half-life versus Mod GRF 1-29's roughly 30-minute half-life.

  • Preservation of natural GH pulsatility (unlike exogenous GH injection)

    Medium

    Mechanistically expected from the GHRH-analog class; not directly measured for this specific compound.

    PMID 20554713 (tesamorelin pooled phase 3, JCEM 2010); mechanistic GH-axis feedback physiology

  • Synergistic GH release with GHRPs (Ipamorelin, GHRP-6)

    Medium

    Human trials show greater GH release combining GHRH and GHRP-6, mostly in patient populations.

    PMID 9509075 (Clin Endocrinol 1998, prolactinoma patients); PMID 7883854 (JCEM 1995, hypothalamopituitary disconnection, mechanistic); PMID 9186261 (Eur J Endocrinol 1997 - narrative review, not primary data)

  • Improved body composition (increased lean mass, decreased fat mass) via GH/IGF-1 axis

    Low

    Class RCT evidence covers only visceral fat loss in HIV lipodystrophy, not general lean-mass gains.

    PMID 20101189 (Falutz, JAIDS 2010); PMID 20554713 (pooled phase 3). PMID 22495074 removed: it reports metabolic-profile improvement associated with visceral fat loss, not the body-composition claim itself.

  • Improved sleep quality and recovery (associated with GH-pulsatile release during sleep)

    Speculative

    Small human GHRH studies show mixed, sex-dependent sleep effects; recovery benefit is unstudied.

    PMID 17850984 (Psychoneuroendocrinology 2007, impaired sleep in women); PMID 16912060 (Am J Physiol 2006, NREM sleep after sleep deprivation); PMID 12823639 (J Intern Med 2003, 'Sleep and endocrinology' - narrative review, background only)

Benefits(6)

  • Dose-dependent increase in growth hormone levels

    Teichman et al., JCEM 2006 (PMID 16352683, n=healthy subjects, two RCTs)

  • Multi-day IGF-1 elevation was demonstrated with CJC-1295 with DAC; this result is not established for Mod GRF 1-29.

    Teichman et al., JCEM 2006 (PMID 16352683)

  • Preservation of natural GH pulsatility (unlike exogenous GH injection)

    GHRH analog class pharmacology; Veldhuis et al., multiple GH pulsatility studies

  • Synergistic GH release with GHRPs (Ipamorelin, GHRP-6)

    Bowers et al., multiple studies on GHRH/GHRP synergy; clinical protocol data

  • Improved body composition (increased lean mass, decreased fat mass) via GH/IGF-1 axis

    Extrapolated from sermorelin and GH secretagogue class data

  • Improved sleep quality and recovery (associated with GH-pulsatile release during sleep)

    Anecdotal and clinical practice reports; GH physiology literature

Key studies(2)

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA

    Journal of Clinical Endocrinology & Metabolism

    2006

    CJC-1295 produced dose-dependent GH increases of 2-10 fold sustained for 6+ days and IGF-1 increases of 1.5-3 fold for 9-11 days after single injection. Half-life 5.8-8.1 days. After multiple doses, IGF-1 stayed elevated for up to 28 days. No serious adverse reactions. Cumulative effect with repeated dosing.

  2. Thorner MO, Rochiccioli P, Colle M, et al.

    Journal of Clinical Endocrinology & Metabolism

    1996

    GRF 1-29 (sermorelin) produced sustained GH release and improved growth velocity in GH-deficient children. Formed the basis for sermorelin (Geref) FDA approval for pediatric GH deficiency.

Regulation & availability

Why researchers look at it

Mod GRF 1-29 is a GHRH analog used to stimulate the body's own growth hormone production in natural pulses rather than injecting synthetic GH. With a GHRP such as Ipamorelin, GH release is synergistic. It is promoted for recovery, body composition, sleep quality, and overall vitality; claimed gains in body composition and sleep are low or speculative.

Estimated cost
No approved product and no verified reference price
FDA status
Mod GRF 1-29 is not FDA-approved for any indication and is not on FDA's list of bulk substances pharmacies may use. FDA identified no applicable USP/NF monograph or approved-drug component basis for non-DAC CJC-1295. An FDA advisory committee voted against adding it in December 2024, its nominations were withdrawn, and no current Category 1 or final bulks-list pathway is established. Related sermorelin was previously approved as Geref; that approval does not extend to Mod GRF 1-29.
WADA status
Prohibited — WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). All GHRH analogs including CJC-1295 (with and without DAC), sermorelin, and tesamorelin are prohibited at all times (in- and out-of-competition) under the WADA Prohibited List. Growth hormone secretagogues are specifically named as a prohibited class.
Prescribability
Mod GRF 1-29 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024.
Availability
Some clinics advertise compounded Mod GRF 1-29, but a prescription does not establish lawful bulk compounding under 503A or 503B. It is not FDA-approved, and no current Category 1 or final bulks-list pathway is established. Sermorelin (unmodified GRF 1-29) was previously FDA-approved as Geref but was discontinued; that former approval does not cover this modified peptide.

International status

  • EU

    Not approved

  • US

    Mod GRF 1-29 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024.

  • Worldwide

    WADA prohibited; widely used in anti-aging clinics globally

Regulatory timeline(8)

  1. 1982
    GHRH (GRF 1-44) isolated and characterized by Guillemin and Vale laboratories
  2. 1990s
    Sermorelin (GRF 1-29) FDA-approved as Geref for GH deficiency in children
  3. 2005
    CJC-1295 with DAC clinical trials conducted; tetrasubstituted GRF 1-29 developed
  4. 2006
    Teichman et al. publish CJC-1295 RCTs in JCEM showing sustained GH/IGF-1 elevation
  5. 2008
    Sermorelin (Geref) voluntarily discontinued by manufacturer (commercial reasons)
  6. 2010s
    Mod GRF 1-29 becomes widely used in anti-aging/regenerative medicine clinics
  7. 2023
    FDA increases scrutiny of compounding pharmacies producing peptides including GHRH analogs
  8. 2026
    No FDA approval or current Category 1 pathway established; PCAC recommended against adding non-DAC CJC-1295 free base and acetate in December 2024.

Sources & FAQs

Research sources(2)

Frequently asked questions(3)

What is the difference between Mod GRF 1-29 and CJC-1295 with DAC?

Both are GHRH analogs with the same core peptide, but CJC-1295 with DAC has a Drug Affinity Complex that binds to albumin, extending its half-life to 5-8 days. Mod GRF 1-29 (without DAC) has a half-life of ~30 minutes. CJC-1295 with DAC also preserved GH pulsatility while increasing basal GH. Superior pulsatility or fewer side effects with Mod GRF 1-29 has not been established in a comparative trial.

How does Mod GRF 1-29 compare to direct GH injections?

Direct GH injections provide a flat, supraphysiological dose that bypasses the pituitary. Mod GRF 1-29 stimulates the pituitary to release GH in natural pulses, preserving feedback mechanisms. This is considered safer, more physiological, and less likely to cause GH-related side effects like insulin resistance and joint pain.

What is the difference between Mod GRF 1-29 and sermorelin?

Sermorelin is the original unmodified GRF 1-29 with a half-life of ~10 minutes. Mod GRF 1-29 has four amino acid substitutions that extend stability and half-life to ~30 minutes, improve binding affinity, and prevent enzymatic degradation. Mod GRF 1-29 is considered the improved version of sermorelin.